Search bioRxiv⌕ Search

bioRxiv · 10.64898/2026.02.15.705970

Magnetic nanobiopsy: A minimal technology for live cell biomolecular sampling

Abstract

Cellular heterogeneity is a fundamental determinant of precision medicine, governing transcriptional plasticity, lineage commitment, and adaptive programs that drive disease progression and therapeutic resistance. However, most molecular interrogation technologies remain inherently destructive, relying on bulk measurements that average cellular signals and systematically obscure rare but functionally decisive subpopulations. As a result, current approaches provide only static snapshots of complex cellular systems, preventing longitudinal analyses of dynamic molecular states and masking the contributions of relapse-initiating, phenotypically plastic, or therapy-resistant cells that ultimately dictate population fate. Here, we present magnetic nanobiopsy, a simple and scalable platform for minimally invasive, repeatable intracellular molecular sampling from living cells. Magnetically actuated nanocomposites (200 nm-1.4 {micro}m) enable efficient intracellular access and stable biomolecular capture while preserving cellular structural and functional integrity. High-resolution imaging and biochemical analyses confirm robust internalization and anchoring of intracellular biomolecules, while flow cytometry demonstrates that the retrieved cargo remains cell-specific and quantitatively representative of the parental heterogeneous population. By enabling longitudinal, single-cell-resolved molecular profiling within intact living populations, magnetic nanobiopsy bridges the gap between static bulk analyses and technically complex single-cell methods. This platform establishes a new framework for real-time investigation of cellular heterogeneity, adaptive responses, lineage diversification, and transient cell-state transitions, with broad applicability in cell biology, oncology, and biobanking. HighlightsO_LIMagnetic nanobiopsy enables non-destructive, longitudinal molecular sampling of living cell populations with high throughput and minimal operational complexity. C_LIO_LIThe nanoprobes bypass endo-lysosomal sequestration, directly interfacing with the cytosol to capture representative protein and RNA cargo via a membrane-preserving budding exit. C_LIO_LIQuantitative validation confirms that the retrieved molecular profiles faithfully mirror the heterogeneity and relative abundance of the parental cell population. C_LI O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=109 SRC="FIGDIR/small/705970v1_ufig1.gif" ALT="Figure 1"> View larger version (32K): org.highwire.dtl.DTLVardef@1e0bee0org.highwire.dtl.DTLVardef@13a5b6org.highwire.dtl.DTLVardef@1e48f5dorg.highwire.dtl.DTLVardef@805b08_HPS_FORMAT_FIGEXP M_FIG C_FIG A magnetic nanobiopsy platform is presented for the longitudinal, non-destructive molecular sampling of living cell populations. Magnetically actuated nanocomposites directly access the cytosol--bypassing endo-lysosomal sequestration--to recruit a representative cargo of proteins and RNA through surface interactions and mechanical dragging. Guided by a changing external magnetic field, the molecularly loaded nanoparticles reversibly traverse the plasma membrane and exit via a controlled, budding-like mechanism that ensures cellular integrity. By preserving cell viability and population-level heterogeneity, this approach enables the retrieval of representative biomolecular cargo and the continuous monitoring of dynamic cellular states.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Garcia-Hevia, L., Munoz-Guerra, D., Fanarraga, M. L.. 2026-02-16. Magnetic nanobiopsy: A minimal technology for live cell biomolecular sampling. https://doi.org/10.64898/2026.02.15.705970

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Sequence context and partner availability specify divergent cell fates from a single transcription factor

Transcription factors drive the gene regulatory networks that control developmental transitions, yet which of their many targets a cell uses remains unresolved. Expressing Cebp, Cebp{beta} or Cebp{delta} identically, alone or with Oct4, Sox2, Klf4 and cMyc, gave four outcomes: adipocyte from fibroblasts and neural stem cells, trophectoderm from embryonic stem cells, and myeloid from B cells. Raising Cebp levels changed how many sites it reached, not which sequence it read: clustered motifs maintained somatic enhancers, while spillover onto low-copy sites created de novo enhancers carrying composites of Cebp and cell-type-restricted partners. In fibroblasts, Cebp also redistributed Oct4, Sox2 and Klf4 from early targets, blocking iPSC formation. Supplying the predicted partners rewrote the output: Spi1 redirected Cebp into parallel adipogenic and myeloid programs, via a transient PpargCD45 state using separate enhancers for each; TFAP2C abolished adipogenic conversion. Motif density and partner composites therefore assemble a factor's instructive output in the receiving cell.

cell biology↗

High-content screening identifies FDA-approved activators of mitophagy

Mitochondrial diseases are highly heterogeneous disorders caused by defects in oxidative phosphorylation, for which only limited therapeutic options are available. The elimination of dysfunctional mitochondria via mitophagy activation is an attractive strategy to treat several mitochondrial diseases, irrespective of the underlying genetic defect. To identify pharmacological activators of this pathway, we performed a high-content screening of 1,971 FDA-approved compounds using cellular reporters of TFEB nuclear translocation and mitophagy. This screening identified 294 compounds that promoted TFEB translocation, nine of which increased the number of mitolysosomes without compromising cell viability or damaging mitochondria. Among the selected compounds, Meptazinol and Ponatinib emerged as the top-ranked mitophagy inducers in fibroblasts from patients with complex I and IV deficiency, respectively, and were prioritised for further characterisation. However, they did not rescue the bioenergetic defect, suggesting that the stimulation of mitophagy per se is not sufficient to ameliorate the OXPHOS defect in mitochondrial diseases. Overall, our findings establish a scalable platform for the identification of pharmacological activators of TFEB and identify candidate compounds for therapeutic modulation of mitophagy.

cell biology↗

Matrix Gla Protein deficiency reveals a previously unrecognized mucosal calcification in the mouse airways

Tracheal calcification is a common finding that is considered to have limited clinical significance when detected most often in elderly individuals. Despite its frequent occurrence, the cellular and molecular mechanisms at the origin of tracheal calcification remain largely unexplored. In this context, we aimed to characterize the development of tracheal calcification, and to determine the role of matrix Gla protein (MGP), a major inhibitor of ectopic calcification whose genetic or pharmacologic deficiency is associated with premature tracheal calcification in humans. We found that wild-type mice undergo an unexpected early physiologic calcification of the tracheal cartilage rings beginning around one month after birth. This calcification progresses in a dynamic rostro-caudal sequence through a process involving terminal differentiation of tracheal chondrocytes. These findings challenge the prevailing view that tracheal cartilage is a permanent hyaline cartilage and instead reveals an early and highly organized physiologic calcification process. Furthermore, our findings further identify MGP as a key regulator of calcification within the respiratory tract. Indeed, MGP deficiency not only markedly accelerates tracheal cartilage calcification through a similar pattern and mechanism but also induces a previously unrecognized calcification of the tracheal mucosa, a lesion absent in wild-type mice. These alterations could partly explain the respiratory manifestations observed in MGP-deficient patients having Keutel syndrome, which include dyspnea, cough, stridor, and recurrent infections, symptoms previously being mainly attributed to calcification of the tracheal cartilage rings.

cell biology↗